Rebecca Arend
This is an open-label, Phase 1 clinical study to evaluate the safety, tolerability, PK profiles, and clinical activity of IV and PO arginine supplementation + SOC chemoimmunotherapy regimens in participants with PROC.
This is a Phase I, investigator-initiated and open-label study. Patients will be evaluated and treated at University of Alabama Birmingham Hospital. Patients will receive both oral and IV arginine with the physician choice of paclitaxel, pembrolizumab, +/- bevacizumab or pembrolizumab, bevacizumab, and oral cyclophosphamide, where doses and schedule are consistent with standard of care. Patients who are excluded from the trial due to progression will be scheduled for three- and six-months follow-up evaluations after the last dose. The goal for enrollment will be 6-24 patients with a 3-patient…
Inclusion Criteria: 1. Must be at least 18 years of age 2. ECOG performance status of 0 or 1 (see Appendix A). 3. Patient must be a candidate for either cohort A or cohort B treatment backbone. * For patients enrolling on treatment cohort A, PD-L1 positivity must be ≥1. Patient's with PD-L1 positivity ≥1% can enroll in cohort B at physician's discretion. * If PD-L1 positivity is unavailable or is \<1%, patients can only enroll on treatment cohort B. 4. Patients must have high-grade serous or endometrioid histology 5. Recovery to baseline or ≤ Grade 1 CTCAE v.5.0 from toxicities related…
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Patients will receive one of two SOC options of chemotherapy and immunotherapy with the addition of IV and PO supplemental arginine. Regimen 1 will be pembrolizumab, bevacizumab, and oral cyclophosphamide and regimen 2 will be paclitaxel and pembrolizumab +/- bevacizumab with doses and schedule consistent with standard of care.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.